Respiri (ASX: RSH)

Last close As at 22/06/2024


0.00 (0.00%)

Market capitalisation


Respiri is an ASX-listed company developing SaaS diagnostic solutions to support respiratory health management. Its technology detects wheeze, a typical symptom of asthma, chronic obstructive pulmonary disease and respiratory disease, to provide an objective measure of airway limitation.

Latest Insights

View More

Healthcare | Update

Respiri — Access platform-led growth prospects ahead

Healthcare | Flash note

Respiri — Early onset of synergies from Access acquisition

Healthcare | Flash note

Respiri — Raise anticipated to fund the Access acquisition

Healthcare | Flash note

Respiri — wheezo to access a larger addressable market

Happy children launch a kite in the field at sunset. Little boy and girl on summer vacation



Balance Sheet

Forecast net debt (A$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 4.2 (19.4) (59.7)
Relative 1.8 (25.4) (62.0)
52 week high/low A$0.1/A$0.0


Edison Investment Research is terminating coverage on Respiri (RSH). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 0.8 (6.2) (6.3) (0.87) N/A N/A
2023A 0.7 (5.4) (5.4) (0.67) N/A N/A
2024E 6.6 (1.7) (1.8) (0.20) N/A N/A
2025E 11.9 0.5 0.4 0.03 83.3 8114.2


Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free